Quincy S C Chu
Overview
Explore the profile of Quincy S C Chu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
278
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Melosky B, Juergens R, Banerji S, Sacher A, Wheatley-Price P, Snow S, et al.
Ther Adv Med Oncol
. 2025 Jan;
17():17588359241308784.
PMID: 39776537
Non-small-cell lung cancer (NSCLC) is a highly heterogeneous disease that is frequently associated with a host of known oncogenic alterations. Advances in molecular diagnostics and drug development have facilitated the...
2.
Besse B, Pons-Tostivint E, Park K, Hartl S, Forde P, Hochmair M, et al.
Nat Med
. 2024 Feb;
30(3):716-729.
PMID: 38351187
For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L)1 checkpoint inhibitors, alone or with platinum-doublet therapy. However, not all patients...
3.
4.
Wong S, Chu Q, Spratlin J, Sangha R, McEwan A, Morrish D, et al.
Case Rep Oncol
. 2019 Nov;
12(3):791-795.
PMID: 31762750
Thyroid cancer is the most common type of endocrine malignancy. Cornerstones of thyroid cancer treatment include surgery, radioactive iodine ablation, and thyroid stimulating hormone suppression. The National Comprehensive Cancer Network...
5.
Purcell S, Elliott S, Baracos V, Chu Q, Sawyer M, Mourtzakis M, et al.
Nutr Clin Pract
. 2019 Jul;
34(6):922-934.
PMID: 31347209
Background: Our purpose was to assess the accuracy of resting energy expenditure (REE) equations in patients with newly diagnosed stage I-IV non-small cell lung, rectal, colon, renal, or pancreatic cancer....
6.
Purcell S, Baracos V, Chu Q, Sawyer M, Severin D, Mourtzakis M, et al.
Nutr Cancer
. 2019 Jul;
72(3):431-438.
PMID: 31282744
Understanding resting energy expenditure (REE) is important for determining energy requirements; REE might be altered in individuals with cancer. The objective of this study was to characterize determinants of REE...
7.
Determinants of change in resting energy expenditure in patients with stage III/IV colorectal cancer
Purcell S, Wallengren O, Baracos V, Lundholm K, Iresjo B, Chu Q, et al.
Clin Nutr
. 2019 Apr;
39(1):134-140.
PMID: 30975554
Background & Aims: Resting energy expenditure (REE) is variable in cancer and might be influenced by changes in tumor burden, systemic inflammation, and body composition. The objective of this study...
8.
Conter H, Chu Q
J Oncol Pract
. 2018 Feb;
8(2):69.
PMID: 29447097
Purpose: Pharmaceutical development involves substantial financial risk. This risk, rising development costs, and the promotion of continued research and development have been cited as major drivers in the progressive increase...
9.
Kim C, Chu Q, Fassbender K, Ghosh S, Spratlin J
Am J Clin Oncol
. 2017 Apr;
41(9):867-873.
PMID: 28368922
Objectives: Patients with advanced pancreatic cancer (APC) have a poor prognosis and experience a large burden of disease-related symptoms. Despite advancements in the treatment of APC, survival is dismal and...
10.
Devriese L, Koch K, Mergui-Roelvink M, Matthys G, Ma W, Robidoux A, et al.
Invest New Drugs
. 2013 Dec;
32(3):481-8.
PMID: 24346280
Aim: To quantify the effect of food on the systemic exposure of lapatinib at steady state when administered 1 h before and after meals, and to observe the safety and...